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Abstract
Objective: Under normoxia, non-malignant cells rely on oxidative phosphorylation for their ATP production, whereas cancer
cells rely on Glycolysis; a phenomenon known as the Warburg effect. We aimed to elucidate the mechanisms contributing
to the Warburg effect in human breast cancer.
Experimental design: Lactate Dehydrogenase (LDH) isoenzymes were profiled using zymography. LDH-B subunit
expression was assessed by reverse transcription PCR in cells, and by Immunohistochemistry in breast tissues. LDH-B
promoter methylation was assessed by sequencing bisulfite modified DNA.
Results: Absent or decreased expression of LDH isoenzymes 1-4, were seen in T-47D and MCF7 cells. Absence of LDH-B
mRNA was seen in T-47D cells, and its expression was restored following treatment with the demethylating agent
5’Azacytadine. LDH-B promoter methylation was identified in T-47D and MCF7 cells, and in 25/ 25 cases of breast cancer
tissues, but not in 5/ 5 cases of normal breast tissues. Absent immuno-expression of LDH-B protein (,10% cells stained),
was seen in 23/ 26 (88%) breast cancer cases, and in 4/8 cases of adjacent ductal carcinoma in situ lesions. Exposure of
breast cancer cells to hypoxia (1% O2), for 48 hours resulted in significant increases in lactate levels in both MCF7 (14.0 fold,
p = 0.002), and T-47D cells (2.9 fold, p = 0.009), but not in MDA-MB-436 (-0.9 fold, p = 0.229), or MCF10AT (1.2 fold, p = 0.09)
cells.
Conclusions: Loss of LDH-B expression is an early and frequent event in human breast cancer occurring due to promoter
methylation, and is likely to contribute to an enhanced glycolysis of cancer cells under hypoxia.
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Introduction
Breast cancer is the most common cancer diagnosis and the
leading cause of cancer-related deaths in women worldwide [1].
Moreover, the disease incidence has increased over the past three
decades [2]. Despite advances in early detection and treatment,
around 30% of patients with early-stage breast cancer will develop
recurrent disease, which often presents as metastasis and a poor
prognosis [3].
Normal cells in the presence of oxygen (aerobic conditions),
derive most of their energy from glycolysis coupled with oxidative
phosphorylation which is a highly efficient process yielding 38
molecules of ATP for each molecule of glucose consumed [4].
Glucose enters into the cell and undergoes a series of steps to
generate pyruvate, which then enters into the mitochondria where
it is metabolized to CO2 and water with the formation of ATP.
Furthermore, this process is facilitated by the presence of oxygen
which activates oxidative phosphorylation and inhibits glycolysis
(known as the Pasteur effect), [5,6]. However, when oxygen is
limited (anaerobic conditions), such as following prolonged
exercise, pyruvate undergoes fermentation where it is converted
to lactate by a reaction catalyzed by Lactate Dehydrogenase
(LDH), [7,8].
LDH is a tetrameric enzyme, containing 2 major subunits (A
and B), encoded by 2 different genes, LDH-A and LDH-B [8,9].
The LDH-A and LDH-B subunits associate as tetramers to form 5
different isoenzymes (LDH-1 to LDH-5), which are comprised of
either subunits LDH-B4 (LDH-1); LDH-B3:A1 (LDH-2); LDH-
B2:A2 (LDH-3), LDH-B1:A3 (LDH-4) and LDH-A4 (LDH-5)
subunits. These LDH isoenzymes catalyze the interconversion of
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pyruvate and lactate, which is a key step in the glycolysis pathway
as it also regenerates NAD+, necessary for continued glycolysis
[10]. The LDH-5 isoenzyme which is composed solely of four
LDH-A subunits (LHD-A4), catalyzes the reduction of pyruvate
into lactate with unparalleled efficiency, particularly under
anaerobic conditions [8,11]. However, this function of LDH
gradually decreases as the number of LDH-B subunits compared
to the LDH-A subunits increase. Thus, the LDH-1 isoenzyme
composed solely of four LDH-B subunits, efficiently favours the
backward conversion of lactate into pyruvate [8,10].
In contrast to normal cells, cancer cells derive a major source of
their energy from glycolysis even in the presence of oxygen, despite
the fact that glycolysis alone is an energetically inefficient process,
yielding only 2 molecules of ATP per molecule of glucose
[12,13,14]. This increased glycolysis even in the presence of
oxygen was first described by Otto Warburg in the 1920’s, and is
now known as the Warburg effect or aerobic glycolysis [13,14].
Activation of aerobic glycolysis is thought to be a mechanism used
by cancer cells to liberate them from a dependency on oxygen for
their ATP production, particularly under hypoxic tumour
microenvironments [7]. Furthermore, this altered metabolism of
cancer cells is thought to confer a selective advantage for their
survival and proliferation [10].
Although the precise molecular mechanisms underlying the
Warburg effect are incompletely understood, environmental
(nutrients, hypoxia, acidity, etc), genetic and epigenetic factors
are known to play a role [5,14,15,16]. A role for genetic and /or
epigenetic factors has also emerged from the finding that the
glycolytic phenotype persists in cancer cells isolated from tumours
growing in vivo [5]. Tumour cells have been shown to undergo
aerobic glycolysis following oncogene activation (myc, ras, AKT),
and tumour suppressor (p53, VHL) gene inactivation, which act to
upregulate Hypoxia-Inducible Factor 1 alpha (HIF-1a) levels
[5,7]. Increased HIF-1a, in turn results leads to increased
transcription of genes involved in glucose transport, glycolysis,
and lactate formation through up-regulation of the LDH-A
subunit. Interestingly, the LDH-A subunit has been found to be
frequently up-regulated in clinical tumours and is often associated
with disease progression and a poor prognosis [11,17,18]. In
addition to the above mechanisms contributing to the Warburg
effect, we and others have previously reported absence or
decreased expression of the LDH-B subunit in prostate and
gastric cancers, due to hyper-methylation of the LDH-B promoter
[19,20]. Recently, decreased expression of LDH-B has been
associated with higher histological grade and perineural invasion
in bladder cancer, suggesting that LDH-B may be related to
tumour progression [21].
The aim of the current study was to elucidate the mechanism(s)
contributing to the Warburg effect in human breast cancer. Panels
of human breast derived cell lines representing various stages of
breast cancer development and progression (non-malignant, pre-
malignant, pre-invasive, invasive and metastatic disease), were
profiled for expression of LDH isoenzymes using zymography.
Absent or decreased expression of the LDH-B subunit was seen in
T-47D and MCF7 cells, and the underlying mechanisms were
investigated by sequencing the LDH-B promoter region in bisulfite
modified DNA from the cell lines, and human breast cancer
tissues. Furthermore, functional relevance of the absent or
decreased expression of the LDH-B subunit was investigated by
subjecting both LDH-B deficient and proficient cells to conditions
of hypoxia, and measuring lactate levels as an indicator of their
dependency on glycolysis.
Materials and Methods
Cell lines and culture
Human breast cancer cell lines MDA-MB-436, MDA-MB-231,
MCF7, T-47D, and the prostate cancer cell line LNCaP were
obtained from the American Type Culture Collection (ATCC),
(http://www.atcc.org/). The MCF10A, MCF10AT and
MCF10DCIS.com breast epithelial cell lines, representing normal
(immortalized) breast epithelial cells, pre-malignant and pre-
invasive ductal carcinoma in situ (DCIS) disease respectively [22],
were a kind gift from the Barbara Ann Karmanos Cancer
Institute, Detroit, Michigan, USA. The LNCaP-LN3 prostate
cancer cell line used as a positive control was a kind gift from Dr.
Curtis Pettaway (MD Anderson Cancer Centre, USA), [23]. The
MCF7, MDA-MB-436 and MDA-MB-231 cells were maintained
in RPMI-1640 media containing Glutamax, supplemented with
10% fetal calf serum and Penicillin/ Streptomycin (Gibco-BRL,
Paisley, United Kingdom). The T-47D cells were cultured in
DMEM containing Glutamax, supplemented with 10% fetal calf
serum and Penicillin/ Streptomycin (Gibco-BRL). The MCF10A,
MCF10AT and MCF10DCIS.com cells were cultured in
DMEM/F12 Advanced media supplemented with Penicillin/
Streptomycin, 5% horse serum, 10 mM HEPES, 10 mg/ml
insulin, 20 ng/ml EGF, 100 ng/ml cholera toxin and 0.5 mg/ml
hydrocortisone. All cells were confirmed to be free from
Mycoplasma using the EZ-PCR Mycoplasma test kit (Geneflow
Ltd, UK).
Short tandem repeat profiling of cells
In order to confirm the authenticity of representative breast cell
lines, DNA from MCF7, T-47D and MCF10 was analyzed by
Short Tandem Repeat (STR) profiling of 10 loci, at the University
of Sheffield Core Genomics facility (http://genetics.group.shef.ac.
uk/), using the StemEliteTM ID system (Promega, Product code:
G9530), and the products run on a ABI 3730 DNA analyzer,
according to the manufactures instructions. STR matches were
searched using the LGC standards database (may 2012): http://
www.lgcstandardsatcc.org/ATCCCulturesandProducts/
CellBiology/STRProfileDatabase/tabid/986/Default.aspx. The
STR profiles of the cells tested were as expected with 18/18
matching alleles, thus confirming their authenticity.
Patient tissue material
Archived paraffin-embedded tissues obtained from patients
having surgery for breast cancer at the Royal Hallamshire
Hospital were used. Prior local ethics committee approval (South
Yorkshire Research Ethics reference: 09/H1310/54), and in-
formed patient consent was obtained in all cases. Genomic DNA
was extracted from micro-dissected tissue sections as previously
described [24], and used for sequence analysis. In addition,
genomic DNA extracted from 5 cases of normal human breast
tissue was purchased from Ambsbio (www.ambsbio.com), with
patient ages ranging from 21-83 yrs. For sequencing of the LDH-B
gene promoter region, 25 cases of adenocarcinoma were used
which comprised of grade 1 (n= 5); grade 2 (n= 10), and grade 3
(n= 10) tumours. For immunohistochemistry, 26 cases of adeno-
carcinoma were used; 18 of which were also used for DNA
sequence analysis.
Zymography for lactate dehydrogenase isoenzymes
Zymography for LDH isoenzymes was performed using
cellulose acetate membranes (Helena Biosciences, Titan III
(94676 mm)), with Tris-Glycine buffer according to the supplied
manufacturer’s instructions and as previously described [25].
LDH-B Promoter Methylation in Human Breast Cancer
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Following electrophoresis, the gels were placed in 10 ml of staining
solution containing 5 mM NAD, 50 mM lithium lactate, 0.1 mM
Tris-HCl (pH 8.6), 0.2 mM Phenazinmethosulphate (PMS),
2.0 mM nitrobluetetrazolium (NBT), and 0.8 mM (3-(4,5-Di-
methylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT), and
the colour was allowed to develop (3- 6 min) in the dark at 37uC.
Reverse transcription PCR
Total RNA was extracted using TRI Reagent (Sigma-Aldrich,
Dorset, UK), according to the manufacturer’s instructions. After
precipitation, the RNA pellet was washed three times with 75%
ethanol. RNA was quantified spectrophotometrically. RNA (2 mg)
was reverse transcribed into cDNA using the SuperScriptH III
First-Strand Synthesis System (Invitrogen, Paisley, UK), with
250 ng of random primers, according to the manufacturer’s
instructions. LDH-B mRNA expression was assessed by reverse
transcription PCR (RT-PCR), using primers and conditions as
previously described [19].
Sequencing of sodium bisulfite-modified DNA
DNA was extracted from breast cancer cell lines using the
Gentra Puregene cell kit (Qiagen), according to the supplied
manufacturer’s instructions. Prior to sequencing, DNA was subject
to sodium bisulfite-modification using the CpGenomeTM DNA
modification kit (Invitrogen), according to the supplied manufac-
turer’s instruction manual. For sequencing of the LDH-B
promoter region, sodium bisulfite-modified DNA was amplified
using previously published PCR primer sequences and conditions
[19]. Only those cases showing an intense single PCR band
following electrophoresis through a 2% agarose gel were excised
and subject to sequence analysis. Sequencing of bisulfite modified
DNA was performed at the University of Sheffield Core Genomics
facility and the chromatograms visualized using the freely
downloaded Chromas software (http://www.technelysium.com.
au/chromas.html).
Hypoxic cell culture
For the hypoxic cell culture experiments, T-47D, MCF7, MDA-
MB-436, and MCF10AT cells were initially cultured under
normoxic conditions as described above. Cells were then
trypsinized and plated into T25cm2 flasks, and the flasks
transferred into a normoxic (21% O2) incubator, or hypoxic (1%
O2) chamber, as previously described [26]. The cell culture
medium used for hypoxic growth had been pre-equilibrated to the
same oxygen tension as in the hypoxic chamber for 6 hours.
Lactate levels in the conditioned medium were measured following
48 hours of cell growth under hypoxic or normoxic conditions.
Lactate measurements
Lactate concentrations in the conditioned medium were measured
using a protocol available from the Sigma Aldrich website: http://
www.sigmaaldrich.com/etc/medialib/docs/Sigma/Enzyme_Assay/
llacticacidmw.Par.0001.File.tmp/llacticacidmw.pdf. Briefly, the assay
depends on the reduction of NAD+ to NADH and a change in
absorbance, which is proportional to the concentration of lactate in
the medium. A standard curve was constructed using lactate
concentrations ranging from (0–1000 mM lactate). In addition,
lactate concentrations were assayed at the Department of Clinical
Chemistry, Royal Hallamshire Hospital, Sheffield, using a Roche 501
analyzer, and the Lact2 lactate Gen.2 assay (Roche). Lactate levels
were expressed as mM per million cells, by counting the final cell
numbers using a coulter counter (Beckman Coulter model Z2), and
after subtracting the values for the basal lactate levels present in the
unconditioned media.
Immunohistochemistry and scoring of staining
Immunohistochemistry for expression of the LDH-B protein in
human breast tissue sections was performed as previously
described, using 3,3’-Diaminobenzidine (DAB) as the chromogen
[19]. The anti-LDH-B antibody used has previously been shown
to be LDH-B specific and non-reactive against LDH-A [27].
Immunostained sections were assessed by 2 independent histopa-
thologists (BP and MA), and the percentage of cells stained
recorded. Relevant tissue areas scoring ,10% of stained cells were
recorded as showing absent LDH-B expression, while tissues
showing $10% of stained cells were recorded as showing
expression. Images were taken using a Nikon Eclipse 80i
microscope attached to a Nikon digital camera (DS-2mv), and
the images acquired using the Nikon Nis-Elements imaging
software.
5’- Azacytidine treatment
T-47D cells were cultured in T75 cm2 flasks to ,20%
confluence. A final concentration of 1 mM freshly prepared 5’-
azacytidine (Sigma-Aldrich), was added to the culture medium and
the drug containing medium was changed every 2 days [19]. After
5 days of treatment, total RNA was isolated using TRI reagent
(Sigma) as described above. The RNA was quantified and 200 ng
was used for RT-PCR as described above.
Statistical Analysis
All statistical analyses were performed using GraphPad Prism
(version 5.02).
Results
LDH isoenzymes are absent or decreased in T-47D and
MCF7 cells
Following visualization of the stained zymography gel, absent or
decreased expression of LDH isoenzymes 1–4 were seen in T-47D
and MCF7 cells, with the isoenzyme pattern being similar to the
LNCaP-LN3 prostate cells used as a control (Figure 1). In contrast,
expression of LDH isoenzymes 1–4 were seen in both MDA-MB-
436 and MDA-MB-231 cell lines, although these cells showed
absent or reduced expression of the LDH-5 isoenzyme. Expression
of LDH isoenzymes 2–5 were prominent in the MCF10AT,
MCF10DCIS.com and MCF10A cells. Interestingly, in
MCF10AT, MDA-MB-436, MDA-MB-231, MCF10DCIS.com
and MCF10A cells, an additional band was visible just below the
LDH-4 isoenzyme band (Figure 1, arrowhead). This may
represent posttranslational modified forms of the LDH protein,
since it has been reported that LDH may be subject to several
posttranslational modifications such as phosphorylation, acetyla-
tion and methylation [28].
LDH-B promoter is methylated in T-47D and MCF7 cells
In mammals, DNA methylation of cytosine residues located at
5’ to guanine residues (CpG sites), represents a major epigenetic
mechanism for regulating gene expression, including X-chromo-
some inactivation and genomic imprinting [29]. DNA hyper-
methylation has been shown to result in gene silencing with
consequent loss of gene expression. To understand the mecha-
nisms underlying the absent or decreased expression of the LDH-B
subunit as seen in the T-47D and MCF7 cells, we sequenced the
LDH-B promoter region in these and the other breast cell lines.
LDH-B Promoter Methylation in Human Breast Cancer
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Sequencing of bisulfite modified DNA showed methylation of the
LDH-B promoter region in both T-47D and MCF7 cells (Figure
2a), while the LDH-B expressing cells; MDA-MB-436, MDA-MB-
231, MCF10A, MCF10AT, were all seen to be unmethylated.
LDH-B promoter methylation is frequent in breast cancer
tissues
Sequencing of the LDH-B promoter region in DNA extracted
from 25 cases of human breast cancer tissues of various grades (1–
3), showed evidence of LDH-B promoter methylation in all 100%
(25/25) cases (Figure 2b). Careful examination of all 14 of the
CpG sites within the amplifed promoter region, determined that
all of the sites showed evidence of methylation in tumour tissues
and the methylated breast cancer cell lines. In contrast, LDH-B
promoter methylation was absent in all 5 cases of normal breast
tissue DNA (Figure 2c), in peripheral blood lymphocytes from
matched (n= 10), or unmatched patients (n = 15) (Figure 2d), and
in normal breast skin epithelium (n= 13), used as control tissues. In
these cases, an absence of methylation was noted at all 14 of the
CpG sites within the promoter region analysed.
LDH-B protein expression is absent in breast cancer and
pre-invasive lesions
Immunoexpression of the LDH-B protein was assessed in 26
cases of breast cancer tissues, which in some cases included
adjacent pre-invasive DCIS lesions and non-malignant glands.
Following microscopic examination, LDH-B protein expression
was seen to be localized to within the cytoplasm of non-malignant
glands, in 4/ 8 cases of DCIS lesions and in 3/ 26 cases (12%), of
breast cancers (Figure 3a & 3b). However, absent expression of
LDH-B protein expression was seen in 23/26 (88%) cases of breast
cancer, and in 4/8 (50%) cases of adjacent DCIS lesions (Figure 3c
& 3d).
Re-expression of LDH-B mRNA by 5’-azacytidine
treatment
We next tested the ability of the DNA methyltransferase
inhibitor, 5’-Azacytidine [30], to restore expression of the LDH-B
mRNA in T-47D cells, which were seen not to express LDH-B
mRNA by RT-PCR (Figure 4). Treatment of T-47D cells with 5’-
Azacytidine for 5 days showed re-expression of the LDH-B
mRNA.
Hypoxia leads to increased lactate levels in LDH-B
deficient breast cancer cells
It has previously been reported that the LDH-A subunit is
highly efficient at converting pyruvate to lactate particularly under
hypoxic conditions [8,16]. We therefore investigated the effects of
hypoxia on both LDH-B promoter methylated (T-47D and
MCF7), and unmethylated (MDA-MB-436, MCF10AT) cells, as
the T-47D and MCF7 cells were seen to predominantly express
the LDH-A4 (LHD-5) isoenzyme. All 4 cell lines were cultured
under conditions of normoxia (21% O2), or hypoxia (1% O2) for
48 hours, and lactate levels were measured in the conditioned
medium as described above. Following hypoxic growth, mean
lactate levels in the conditioned medium from MCF10AT cells
increased from 27.9 mM to 33.6 mM per 16106 cells (1.2 fold
change), but this difference was not statistically significant
(p = 0.09, Mann Whitney test), (Figure 5). In MDA-MB-436 cells
the mean lactate levels decreased slightly from 38.5 mM to
34.5 mM per 16106 cells (-0.9 fold change), but was not statistically
significant (p = 0.229). However, following hypoxic growth of
MCF7 cells, mean lactate levels increased significantly (p = 0.002),
from 2.9 mM to 40.7 mM per 16106 cells (14.0 fold change).
Similarly, in T-47D cells the mean lactate levels were found to
increase significantly (p = 0.009), from 15.2 mM to 43.5 mM per
16106 cells (2.9 fold change) following hypoxic growth (Figure 5).
In order to determine the effects of hypoxia on LHD-5
isoenzyme activity, T-47D cells were cultured under both
normoxic and hypoxic conditions and subjected to zymography
analysis. As expected, the LDH-5 isoenzyme activity was seen to
increase following hypoxic growth (Figure 6), since hypoxia has
previously been shown to elevate expression of the LDH-A subunit
[11,17].
Discussion
It has been known since the 1920’s that cancer cells derive a
major source of their energy by aerobic glycolysis; a phenomenon
known as the Warburg effect, in contrast to normal cells which rely
mainly on oxidative phosphorylation [6,12,14]. Although the
precise mechanism(s) for the altered metabolism in cancers is
unknown, previous studies have demonstrated diverse mecha-
nisms, including oncogene activation, tumour suppressor gene
inactivation, hypoxia, up-regulation of the LDH-A subunit, and
absent or decreased expression of the LDH-B subunit
[5,14,15,16,19]. Our current study has shown for the first time
in human breast cancer that loss of expression of the LDH-B
subunit may occur at an early (DCIS) stage, and occurs in a high
frequency of breast cancers, with the underlying mechanism likely
to involve methylation of the LDH-B promoter. Furthermore,
since the LDH-B deficient cells showed significantly increased
lactate levels when exposed to hypoxic conditions, the loss or
reduction in LDH-B expression may provide these cancer cells
with a growth and survival advantage. In addition, the finding of
absent or reduced expression of the LDH-B subunit in 2 widely
used human breast cancer cell lines (T-47D and MCF7), could
Figure 1. Zymography of human breast cell lines. Note the
absent or decreased expression of LDH isoenzymes 1–4 in T-47D and
MCF7 cells. In contrast, expression of LDH isoenzymes 1–4, can be seen
in MDA-MB-436 and MDA-MB-231 cells. Expression of LDH isoenzymes
2-5, are predominant in the MCF10AT, MCF10DCIS.com and MCF10A
cells. The expression of all 5 LDH isoenzymes can be seen in LNCaP cells,
while absent or decreased expression of LDH isoenzymes 1–4, can be
seen in the LNCaP-LN3 cells used as controls. In MCF10AT, MDA-MB-
436, MDA-MB-231, MCF10DCIS.com and MCF10A cells, a weak band
(arrow head), can be seen under the LDH-4 isoenzyme band, and may
represent a posttranslationally modified form of LDH [28].
doi:10.1371/journal.pone.0057697.g001
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have consequences for data interpretation during the use of these
cell lines in metabolic or other studies.
By investigating a range of breast cell lines for their LDH
expression profile, we have shown that the T-47D and MCF7 cells
predominantly express the LDH-5 (LDH-A4) isoenzyme, with
relatively low levels of the LDH-4 (LDH-A3:B1) isoenzyme.
Although our results are in stark contrast to the data reported by
Hussien and Brooks (2011), who showed that MCF7 cells
expressed mainly the LDH-B subunit [31], our data are in partial
agreement with those reported by Burke et al., (1978), who showed
that MCF7 cells expressed only the LDH-5 isoenzyme [32]. The
difference between our data and those reported by Burke et al.,
(1978), may be related to technical factors such as differences in
the sensitivity of the staining procedure, amounts of protein loaded
or the possibility that the LDH-B gene promoter may have
become unmethylated in a small proportion of MCF7 cells to
allow re-expression of the LDH-B protein, which could explain the
relatively low level expression of the LDH-4 isoenzyme seen in the
MCF7 cells (Figure 1). The possibility that the MCF7 cells were
contaminated with another cell line can be firmly ruled out from
our STR profiling data, which authenticated these cells.
Due to the absent or decreased expression of the LDH-B
subunit, T-47D and MCF7 cells were seen to express predomi-
nantly the LDH-5 (LDH-A4), and LDH-4 (LDH-A3:B1) isoen-
zymes, which are enriched for the LDH-A subunit. This data is in
agreement with a previous study showing that LDH-A is the
predominant isoform expressed in breast tissue [33]. Other studies
have demonstrated a critical role for LDH-A in promoting the
growth of breast and other cancer types. For instance, silencing the
expression of LDH-A has been shown to decrease cellular
proliferation and tumourigenic ability of breast cancer cells [34],
and furthermore LDH-A has been shown to be involved in tumour
progression [35].
Previous studies have reported that the glycolytic rate in
cultured cells appears to correlate with tumour aggressiveness [5].
Thus, it has been reported that the non-invasive MCF7 cells have
a much lower aerobic glucose consumption rate compared with
the highly invasive MDA-MB-231 breast cancer cell line [5].
Although this finding is in line with our data where we found that
during conditions of normoxia, lactate levels were higher in the
highly invasive MDA-MB-436 cells compared with MCF7 cells,
we did not expect this finding based on the LDH isoenzyme
profiles observed in these cells. Since the MCF7 cells are deficient
in LDH-B, even under normoxic conditions they were expected to
show higher levels of lactate production due to their expression of
LDH-A, which is the subunit that has the highest efficiency for the
Figure 2. Sequencing chromatograms of sodium bisulfite modified DNA. Methylation at CpG sites (marked by arrowheads), can be seen in
(a) T-47D cells and in (b) a case of human breast cancer tissue by the presence of unmodified CpG residues (arrowheads). Identical sites can be seen to
be modified and therefore unmethylated in (c) normal human breast tissue and (d) peripheral blood lymphocyte DNA from a patient with breast
cancer.
doi:10.1371/journal.pone.0057697.g002
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conversion of pyruvate to lactate [8,10]. These findings suggest
that there are factors other than the loss of LDH-B expression,
which may underlie the Warburg effect in human breast cancer.
Tumour cells are periodically exposed to hypoxic and normoxic
environments [5]. Following hypoxic growth, we measured
significant changes in lactate levels in the LDH-B deficient
MCF7 and T-47D cells, whereas the LDH-B proficient
MCF10AT and MDA-MB-436 cells showed insignificant changes,
compared to normoxic growth conditions (Figure 5). Thus, our
data show that cells with absent or decreased expression of LDH-B
(but express LDH-A), may be better adapted to hypoxic growth by
up-regulating fermentative glycolysis. Even under normoxic
conditions, we were expecting breast cancer cells with absent or
decreased expression of LDH-B to show relatively higher levels of
lactate production [8,10]. However, we observed the opposite
result, in that cells with absent or decreased LDH-B expression
had relatively low levels of lactate production under normoxic
conditions. Thus, our data suggest that under normoxic growth
conditions, breast cancer cells which express both LDH-A and
LDH-B subunits rely on glycolysis for their energy production, as
evidenced by the relatively higher rates of lactate production, and
this is maintained even under hypoxic conditions. In contrast, cells
with absent or decreased expression of LDH-B (but express LDH-
A), under normoxic conditions rely mainly on non-glycolytic
pathways for their energy production, but under hypoxic
conditions may switch to fermentative glycolysis for their energy
production. This data is in keeping with other published data
suggesting that certain tumours may rely more on non-glucose
carbon sources, even in glucose replete conditions [36].
Previous studies have shown that lactate plays a number of key
roles in cancer development, progression and metastasis
[10,37,38]. For instance, in colorectal cancer a study has shown
that lactate can be extruded from cancer cells into the extracellular
matrix and subsequently taken up by tumour-associated stromal
fibroblasts to be used as a fuel [39]. Additionally, lactate may
constitute an alternative metabolic fuel for cancer cells, as
oxidative tumour cells can use lactate in preference to glucose,
thereby sparing glucose to fuel hypoxic tumour cell growth [37]. In
tumours with increased glycolysis and consequently increased
lactate production, the extracellular pH has been shown to be
acidic [40,41]. Furthermore, a low pH has been shown to
stimulate in vitro invasion and in vivo metastasis of cancer cells [42].
Clinical based studies in patients with cervical cancer or head and
neck squamous cell cancer (HNSCC), have shown lactate levels to
be inversely correlated with patient survival [38]. Thus, our
finding of increased lactate levels in breast cancer cells with absent
or reduced expression of the LDH-B subunit when exposed to
Figure 3. Immunoexpression of LDH-B in human breast tissues.
(a) Strong cytoplasmic expression of LDH-B protein can be seen in the
glands of non-malignant epithelium (x20 magnification), and (b) in a
case of pre-invasive DCIS lesion (x10). (c) A DCIS lesion (marked by
asterix) showing absent expression of LDH-B, while strong expression
can be seen in the adjacent and surrounding non-malignant glands
(x10). (d) A breast cancer case showing absent LDH-B expression, while
expression can be seen in non-malignant glands at the top left of the
image (x10).
doi:10.1371/journal.pone.0057697.g003
Figure 4. Reverse-transcription PCR for LDH-B mRNA. Untreated
(U) T-47D cells showed an absence of LDH-B mRNA expression.
Treatment (T) of cells with 1 mM 5’-Azacytidine for 5 days, was able to
restore mRNA expression. GAPDH was used as a loading and
amplification control.
doi:10.1371/journal.pone.0057697.g004
Figure 5. Lactate levels in conditioned medium from breast cell
lines under normoxia and hypoxia. Following hypoxic growth,
mean lactate levels in the conditioned medium from MCF10AT cells
increased from 27.9 mM to 33.6 mM per 16106 cells (1.2 fold change),
but this difference was not statistically significant (p = 0.09, Mann
Whitney test). In MDA-MB-436 cells the mean lactate levels decreased
slightly from 38.5 mM to 34.5 mM per 16106 cells (-0.9 fold change), but
was not statistically significant (p = 0.229). However, following hypoxic
growth of MCF7 cells, mean lactate levels increased significantly
(p = 0.002), from 2.9 mM to 40.7 mM per 16106 cells (14.0 fold change).
Similarly, in T-47D cells the mean lactate levels were found to increase
significantly (p = 0.009), from 15.2 mM to 43.5 mM per 16106 cells (2.9
fold change), following hypoxic growth. * indicate statistically
significant differences (p,0.05).
doi:10.1371/journal.pone.0057697.g005
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hypoxic conditions, suggests that the increased lactate levels may
contribute to fuel aggressive tumour behavior.
The glycolytic phenotype has been shown to coincide with the
transition from pre-malignant lesions to invasive cancer [5]. This
finding is in agreement with our data from breast cancer, since by
immunohistochemistry we found LDH-B protein to be expressed
in 4/ 8 pre-invasive DCIS lesions, but an absence of expression in
the adjacent cancer. However, LDH-B protein expression was
found to be absent in the remainder 4/ 8 cases of DCIS lesions,
which suggests that the loss of LDH-B protein expression may
occur earlier than previously reported i.e. during the transition
from non-malignant epithelium to pre-invasive DCIS lesions. In
support of this, Ong and colleagues reported an increase in glucose
consumption in pre-malignant intestinal polyps and cancers
compared with non-malignant mucosa [43].
Despite the gaps in our knowledge concerning the glycolytic
phenotype, our data showing absent or decreased expression of the
LDH-B subunit, may open up a new therapeutic strategy for the
treatment of breast and other cancer types. Targeting the
remaining LDH-A subunit with therapeutic agents, specifically
in those tumours with an absent or decreased expression of LDH-
B is expected to lead to a greater cell death, as this is expected to
inhibit all cellular LDH activity, and lead to a depletion of the
NAD+ stock necessary for self-sufficient glycolysis to occur. In
support of this idea, a recent study has shown that specifically
targeting the LDH-A subunit using a small molecule inhibitor
(FX11), or by siRNA knock-down, increased cell death and
inhibited the progression of tumours in vivo [35]. Furthermore,
MCF7 cells (with decreased expression of LDH-B), were highly
sensitive to growth inhibition by FX11 [35]. Interestingly studies
on naturally occurring LDH-A null patients have shown that such
patients do not usually develop symptoms during normal
physiological conditions, although excessive fatigue and myoglo-
bulinuria have been noted after intense anaerobic exercise [44].
Taken together with published data, our study provides promising
evidence for the possibility that the LDH-A subunit may be a safe
’drugable’ target for the development of novel anti-cancer agents
[45]. Future efforts should therefore be focused on developing
non-toxic and highly specific small molecule inhibitors of the
LDH-A subunit, in order to block glycolysis, particularly in those
tumours which have absent or decreased expression of the LDH-B
subunit, thus, ’cutting-off’ a major pathway used by breast and
other cancer cells for their energy production.
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